Dhampur Bio Organics Limited has announced the board approval for establishing a wholly owned subsidiary in the United Arab Emirates, marking a significant step in the company's international expansion strategy. The decision was taken during the Board of Directors meeting held on February 26, 2026, with formal disclosure made to stock exchanges under SEBI regulations.

Board Meeting and Regulatory Disclosure

The Board of Directors meeting commenced at 12:30 P.M. (IST) and concluded at 02:10 P.M. (IST) on Thursday, February 26, 2026. Following the approval, the company issued formal notifications to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subsidiary Investment Structure

The new subsidiary will be established as a wholly owned entity of Dhampur Bio Organics Limited, ensuring complete control and ownership by the parent company. The financial commitment represents a strategic investment in the Middle East market:

Business Operations and Industry Focus

The UAE subsidiary will operate across multiple segments within the food and consumer goods sector, leveraging the region's strategic position as a trading hub:

• Trading and distribution of sugar products
• Packaging of sugar and other FMCG products
• Futures trading in sugar and allied products
• Distribution of various FMCG items

This diversified approach positions the subsidiary to capture multiple revenue streams within the regional market while expanding Dhampur Bio Organics' international footprint.

Regulatory Compliance and Approvals

The incorporation process adheres to comprehensive regulatory requirements across multiple jurisdictions as outlined in the company's formal disclosure:

Implementation Timeline

While the board has granted approval, the actual incorporation remains pending approval from relevant UAE authorities. The company has committed to providing necessary updates regarding the subsidiary's name and incorporation details once the wholly owned subsidiary is formally established and receives regulatory clearance. The formal disclosure was signed by Company Secretary & Compliance Officer Ashu Rawat on February 26, 2026.

Dhampur Bio Organics Ltd has announced the complete resumption of manufacturing operations at its Unit Mansurpur facility, marking a significant operational milestone for the company. The announcement was made through a regulatory filing dated January 23, 2026, addressed to both BSE Limited and National Stock Exchange of India Ltd.

Operational Resumption Details

The company confirmed that complete normalcy in manufacturing operations at Unit Mansurpur has been resumed from January 23, 2026. This development follows earlier announcements made by the company on November 13, 2025, and November 14, 2025, regarding operational disruptions at the facility.

Safety and Insurance Coverage

The company emphasized important safety aspects of the incident that led to the operational disruption. Key safety and insurance details include:

• No loss of life or injuries were reported during the incident
• All assets are adequately covered under insurance
• Necessary coordination steps are being undertaken with the insurance company
• The company will keep exchanges informed as required under regulatory guidelines

Regulatory Compliance

The announcement was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, indicating adherence to updated regulatory requirements for such disclosures.

Corporate Communication

The regulatory filing was signed by Ashu Rawat, Company Secretary & Compliance Officer, and was digitally authenticated on January 23, 2026. The communication was addressed to both major Indian stock exchanges where the company's shares are listed, ensuring comprehensive market disclosure of this operational development.